Aclaris Therapeutics Enters Amended ATM Sales Agreement

What Happened
Aclaris Therapeutics, Inc. (ACRS) announced on August 6, 2026 that it entered into a Second Amended and Restated Sales Agreement (the "Amended ATM Agreement") with Leerink Partners LLC and Cantor Fitzgerald & Co. Under the Amended ATM Agreement, Aclaris may, at its sole discretion, offer and sell shares of its common stock from time to time through Leerink and Cantor as sales agents pursuant to a registration statement on Form S-3. The agents will use commercially reasonable efforts to sell shares in "at-the-market" offerings under Rule 415.

Key Details

• Date of filing/entry: August 6, 2026.
• Sales agents: Leerink Partners LLC and Cantor Fitzgerald & Co.
• Commission: Aclaris will pay a 3.0% fee on gross proceeds for shares sold through the agents.
• Mechanics: Sales are "at the market" under Rule 415 and will be made pursuant to an effective Form S-3; Aclaris is not obligated to sell any shares.
• Context: The Amended ATM Agreement amends and restates the prior amended and restated sales agreement dated February 27, 2025 (which had provided for up to $100.0 million of common stock sales).

Why It Matters
This agreement gives Aclaris a flexible, on-demand way to raise capital by selling common stock into the market when management chooses, subject to Form S-3 registration and market conditions. If the company uses the facility, investors may see dilution to existing shares and net proceeds reduced by the 3.0% sales commission. No shares have been sold under this new agreement as of the filing; investors should watch future SEC filings for any actual share issuances or prospectus supplements.